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Abstract 
Background: The annual turnover of the Indian herbal medicinal industry is about 
Rs. 7,500 crore as against the pharmaceutical industry’s turnover of Rs. 14,500 crores with a 
growth rate of more than 15%. Certainly some regulations are required to keep a check on 
this massive industry. Drugs and Cosmetics Act, 1940 (D& C Act) lays down the regulatory 
and recommendatory standards for Ayurvedic drugs. Objective: The present survey study 
was undertaken to assess the compliance of the D & C Act by the Ayurveda drugs 
manufacturing units. The guidelines laid down by this act formed the basis of the study. 
Materials & Methods: A total of 100 drug labels from 13 different major pharmaceutical 
houses were collected from the market and analysed on the basis of guidelines for labelling 
laid down under D&C Act, 1940. Results: It was found that none of the labels satisfied all 
the guidelines pertaining to labelling standards of the Ayurvedic drugs. It was observed that 
92% drug labels did not mention the API standards of the drugs used while 99% drug labels 
did not mention the part of the plant used.  Conclusions: It was inferred that potentially large 
number of the Ayurvedic drugs being marketed in India are misbranded. 
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Introduction 
In the age of modern technology, 
scientific advancements, consumer 
awareness and the advent of evidence 
based medicine, attention has been given 
towards the quality control and marketing 
of the Ayurveda drugs. In India, there are 
about 14 well-recognized and 86 medium 
scale manufactures of herbal drugs. Other 
than this about 8,000 licensed small 
manufactures in India are on record(1). 
The annual turnover of the Indian herbal 
medicinal industry is about Rs. 7,500 crore 
as against the pharmaceutical industry’s 
turnover of Rs. 14,500 crores with a 
growth rate of more than 15 percent. As 
per study commissioned by the Associated 
Chamber of Commerce and Industry 
(ASSOCHAM), the Indian herbal industry 
is projected to double to Rs.15, 000 crore 
by 2015, from the current 7,500 core 
business. The apex chamber estimates 
global herbal industry to grow to Rs 
70,000 crore by 2015, more than double 
from the current level of Rs 30,000 
crore.(2)  
Certainly some laws are required to 
govern this sector so as to keep a tab on 
drugs being manufactured and consumed 
by people across the nation. Manufacture 
and quality control of Ayurvedic, Siddha 
and Unani (ASU) medicines come under 
the purview of Drugs & Cosmetics Act, 
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1940 (D&C Act), which also incorporates 
the regulatory and recommendatory 
standards for these drugs. Drugs & 
Cosmetics Act, 1940 has a separate 
chapter IV- A(3)  which states all the 
guidelines to be followed for 
manufacturing, packaging & labelling of 
ASU drugs. The latest amendments in this 
chapter were done on 22 March 2013 vide 
a Gazette notification by the Central 
Government(4). This notification laid 
certain new guidelines for labelling of the 
ASU drugs.  
 
Aim & Objectives 
The present study was undertaken 
to evaluate the compliance of Drugs & 
Cosmetics Act, 1940 and rules made there 
under and amended from time to time 
pertaining to labelling standards of 
Ayurveda drugs. 
 
Material & Methods 
A market survey was done and 100 
labels of various Ayurvedic medicines 
were collected from chemists in the state 
of Himachal Pradesh. It was a random 
selection and comprised of classical 
medicine as well as patent/ proprietary 
medicine. In all, the drugs from 13 
different pharmaceutical houses including 
the major pharmacies of India, having 
manufacturing units in different states, 
were collected and studied.  
Misbranded Drugs(5):–  As per 
Rule 33-E Chapter IV-A, an Ayurvedic, 
Siddha or Unani drug shall be deemed to 
be misbranded,– 
a) If it is so coloured, coated, 
powdered or polished that damage is 
concealed, or if it is made to appear of 
better or greater therapeutic value than it 
really is; or 
b) If it is not labelled in the 
prescribed manner; or  
c) If its label or container or 
anything accompanying the drug bears any 
statement, design or device which makes 
any false claim for the drug or which is 
false or misleading in any particular. 
Also, Rule 33-EEC prohibits the 
manufacture for sale or for distribution any 
misbranded, adulterated or spurious ASU 
drugs. 
Rule 33-I states the penalty for 
manufacture, sale etc. of ASU drugs 
including imprisonment up to one year and 
fine not less than twenty thousand rupees 
or three times the value of the drugs 
confiscated, whichever is more 
 Rule 161(5) of the D & C Act, 1940 states 
the mandatory guidelines for labelling, 
packing and limit of alcohol which are as 
under 
(1) There shall be considerably 
displayed on the label of the container or 
package of an Ayurvedic (including 
Siddha) or Unani drug, the true list of all 
the ingredients with their official names( 
for herbal ingredients) along with parts 
used & form of ingredients, in which , it is 
used in the manufacture of the preparation 
together with quantity of each of the 
ingredients incorporated therein and a 
reference to the method of preparation 
thereof as detailed in the standard text and 
Adikarana, as are prescribed in the 
authoritative books specified in the First 
Schedule to the Act & in respect of Patent 
or Proprietary ASU drugs, the true list of 
all ingredients with their official & 
botanical names ( for herbal ingredients) 
along with part used & form of ingredient, 
in which it is used in the formulation, with 
its quantity. 
 Provided that if the list of 
ingredients contained in the medicine is 
large and cannot be accommodated on the 
label, the same may be printed separately 
and enclosed with packing and reference 
be made to this effect on the label. 
(2) The container of a medicine for 
internal use made up ready for the 
treatment of human ailments shall, if it is 
made up from a substance specified in 
Schedule E (1), be labelled conspicuously 
with the words ‘Caution: To be taken 
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under medical supervision’ both in English 
and Hindi language. 
(3) Subject to the other provisions 
of these rules, the following particulars 
shall be either printed or written in 
indelible ink and shall appear in a 
conspicuous manner on the label of the 
innermost container of any Ayurvedic 
(including Siddha) or Unani drug and on 
any other covering in which the container 
is packed namely-- 
(i) The name of the drug. For ASU drugs, 
the name shall be the same as 
mentioned in the authoritative books 
included in the First Schedule of the 
Act. 
(ii) A correct statement of the net content 
in terms of weight, measure or number 
as the case may be. The weight and 
volume shall be expressed in metric 
system. 
(iii) The name and address of the 
manufacturer. 
(iv) The number of the licence under 
which the drug is manufactured. 
 (v) A distinctive batch number, that is to 
say, the number by reference to which 
details of manufacture of the particular 
batch from which the substance in the 
container is taken are recorded and are 
available for inspection. 
 (vi) The date of manufacture. For this 
purpose the date of manufacture shall 
be the date of completion of the final 
products, or the date of bottling or 
packing for issue. 
(vii) The words “Ayurvedic medicine” or 
“Siddha medicine” or “Unani 
medicine” as the case may be. 
(viii) The words “FOR EXTERNAL USE 
ONLY” if the medicine is for external 
application. 
(ix) Every drug intended for distribution to 
the medical profession, as a free 
sample shall, while complying with the 
labelling provisions under clauses (i) to 
(viii), further bear on the label of the 
container the words “Physicians 
sample. Not to be sold” which shall be 
over-printed. 
(x) (a) Preparation (Asavas) with high 
content of alcohol as base  
  
Name of the drug Maximum size of 
packing 
 (i) Karpur Asava  15 ml 
(ii) Ahiphensava  15 ml 
(iii) Mrgamadasava  15 ml 
 
(x) (b) Preparations containing self-
generated alcohol 
Name of the drug Maximum 
content of 
alcohol 
(E
thyl 
alcohol 
v/v) 
Maximum 
size of 
packing 
(i) Mritsanjivani 
Sura 
16 per 
cent 
30 ml. 
(ii) 
Mahadrakshasava 
16 per 
cent 
120 ml 
 
Rule 161-B mentions the expiry 
date of the various drug dosage forms of 
ASU drugs, which has to be 
inconspicuously written on the label. 
 
SCHEDULE J (Rule 106)
 
(5) 
mentions the diseases and ailments (by 
whatever name described) which a drug may 
not purport to prevent or cure or make 
claims to prevent or cure. 
 
The present study was done by taking 
into consideration, the provisions of D&C 
Act pertaining to the labelling & 
packaging of ASU drugs. The features 
inscribed over the labels that have been 
incorporated in the study are as following 
1. Name of Medicine 
2. Classical Ayurvedic Medicine or 
Patent/ Proprietary Medicine, as 
the case may be 
3. API standardization of ingredients 
4. Formulation Composition 
5. Adhar Granth/ Reference 
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6. Official Name of ingredients 
7. Botanical Name of ingredients 
8. Part Used (of ingredients) 
9. Quantity /percentage of ingredients 
10. Form in which ingredient is used 
11. Precautionary warning (Hindi & 
English), if any Schedule E drug is 
used as ingredient 
12. Whether Drugs have been used in 
Shuddha form, for which shodhan 
is required  
13. Manufacturing Address 
14. Manufacturing Licence Number 
15. Batch Number 
16. Date of Manufacture & date of 
Expiry 
17. Whether intended for External use 
18. Dose to be taken 
19. Indication 
20. Whether complies to Schedule J, in 
case of indications 
21. Permitted excipients & colors used 
 
Observations & Results 
A total of 100 different 
formulations from 13 major 
pharmaceutical companies were randomly 
selected and studied. Of these 75 
formulations were proprietary medicines, 
while 25 were classical Ayurvedic 
formulations. There were 18 drugs 
containing poisonous drug as stated under 
Schedule E-1. There was one eye drops 
preparation included in the study. There 
were 3 classical Ayurvedic preparations 
containing self-generated alcohol.( asava-
arishta). (Table -1) 
 
Table -1, Total distribution of type of 
drugs included in the study 
Feature  Total 
number 
Percentage 
Classical Ay. 
Formulations 
25 25% 
Proprietary 
Ay. 
Formulation 
75 75% 
Eye drops 
preparation 
1 1% 
Alcoholic 
preparation 
(asava-arishta) 
3 3% 
 
It was observed that all the 
formulations had the term “Ayurvedic 
medicine”, the manufacturing address, 
license number, batch number, date of 
manufacture and dosage clearly stated on 
the labels (Table-2). Of the total drug 
labels studied, 19 drugs were intended for 
external use only and all of these drugs had 
clear indication regarding their external 
use. 
 
Table-2, Compliance of various features 
pertaining to Labelling according to D&C 
Act, 1940 
Feature  Total 
number of 
formulation
s 
Percentag
e 
The term 
“Ayurvedic 
Medicine” 
100 100% 
Manufacturin
g address  
100 100% 
Licence 
number  
100 100% 
Batch number 100 100% 
Date of 
manufacture 
100 100% 
Indication for 
External Use 
Only 
19 100% 
Dose 100 100% 
 
The formulation composition was 
written completely on 95% drug labels, 
while it was incomplete in 5% cases. It 
was an important observation as these 5% 
cases were found to be of a single 
pharmacy and included only classical 
medicines. Only the main ingredients were 
mentioned. It was found that very few 
pharmacies had indicated on the label, 
whether the ingredients used were of API 
standard or not as depicted in Table No.- 3. 
Only 8% formulations from a renowned 
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Pharmaceutical house had stated that the 
ingredients used were of API standards. 
The Ayurvedic Pharmacopoeia of India 
clearly mentions the official names
(6)
 of 
the medicinal plants which are used as raw 
material for drug manufacturing. The D&C 
Act, makes it mandatory to mention the 
official name as well as Botanical name of 
the herbal ingredients used. Most of the 
compositions had either vernacular names 
or common names written on the labels. 
Official name as per API were mentioned 
on 58% labels while 42% labels did not 
have official name written on them. 
Botanical names were also not given in 
most of the labels which has been 
mandated by the Act. Only 67% 
formulations had the botanical names of 
the ingredients written over the labels 
while 33% did not have botanical names 
written over the labels. Only 1% of the 
labels had specified the part of the plant 
used in composition. The quantity of each 
ingredient used was written completely on 
95 % drug labels, while it was not written 
in 5% cases. (Table-3).  
 
Table- 3, Distribution of Non Compliance 
of various features of Labelling  
Feature Compliance  Non 
Compliance 
Formulation 
Composition 
95% 5% 
API 
Standard of 
Ingredients 
8% 92% 
Official 
Name 
58% 42% 
Botanical 
Name 
67% 33% 
Part Used 1% 99% 
Quantity of 
ingredient 
used 
95% 5% 
Expiry date 95% 5% 
Indication of 
the drug 
83% 17% 
Schedule J 
provisions 
94% 6% 
The D&C, Act under rule 161-B 
mentions the expiry date of almost all drug 
dosage forms. However in our study 5 % 
drugs did not have any mention of the 
expiry date. Even if a drug has indefinite 
expiry period, a mention of such should be 
made on the label. The indication for 
which the drug is intended to be used 
should be depicted on the label. However, 
it should not contradict the provisions as 
laid down under Schedule (Sch) J, which 
bars the claim of the drug to cure or heal 
certain disease as mentioned under it. 
Keeping this rule in view, 6 % drugs were 
found to be violating the provision of Sch. 
J (Table-3). The indications mentioned on 
these drugs included obesity, liver 
disorders, uterine disorders, diabetes.  
Of the total drug labels studied, 18 
had contents falling under Schedule E list. 
Out of these 18 drugs the caution warning 
was mentioned on 15 labels in both 
languages. (Table-4) 
 
Table- 4, Schedule E specifications on 
labels  
No. of drugs containing 
Sch E drugs 
Percentage  
18 18% 
Caution warning mentioned on labels in 
both languages. 
15 83.33% 
It was observed that 32 drugs had 
ingredients which were required to be used 
after Shodhan. Hence it should be 
mentioned on the label, whether Shodhit 
drug has been used or not in composition. 
Of these 40.62 % (13 Drugs) drugs did not 
mention, if the “Shodhit” ingredient was 
used, while 59.38% (18 drugs) mentioned 
on the label (table-5), the ingredients were 
used after Shodhan. 
All the drug labels studied had 
indicated the permitted excipients used, 
preservatives added, if any and the colour 
permitted.( Table -6) 
Table- 5, Distribution of drugs in which 
one or more ingredient is required to be 
used after Shodhan 
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Total 
number of 
Labels 
containing 
the 
ingredients 
required to 
be used 
after 
Shodhan 
Whether 
ingredient 
is used 
after 
Shodhan as 
mentioned 
on label 
(%age) 
Not used 
after 
Shodhan as 
mentioned 
on label 
(%age) 
32 59.38% 40.62% 
 
Table-6, Compliance of various features 
pertaining to Labelling according to D&C 
Act, 1940 
Feature Complianc
e  
Non 
Complianc
e 
Permitted 
Excipients 
100% 0% 
Preservative
s 
100% 0% 
Permitted 
Colours  
100% 0% 
 
Of the total drugs studied, only one 
drug came under the purview of Schedule 
FF, as it was an eye drop. (Table-1) It 
complied with all the provisions of the 
schedule. 
 
Discussion  
The present study was undertaken 
to evaluate the impact of Drugs & 
Cosmetics Act and its implementation 
pertaining to the labelling standards of 
Ayurvedic drugs. The Government of 
India closely monitors the standards of all 
the drugs being manufactured & marketed 
in India and takes various steps at 
improving the quality and standards of 
these medicines
(7)
. Various notifications 
and amendments in D&C Act, from time 
to time are an ample proof of close vigil of 
the Central Government on the 
pharmaceutical industry.  
Almost all the major players of the 
Ayurvedic pharmaceutical industry were 
included in this study and it was observed 
that potentially higher percentage of drug 
labels do not comply to the provisions of 
Rule 33-E (b) of D&C Act, thus rendering 
them as Misbranded Drugs. If these big 
pharmacies do not follow the provisions of 
the Act, then the quality of drugs 
manufactured by other 8000 small 
pharmacies can very well be imagined. 
Though the basic information like 
the term “Ayurvedic Medicine”, 
Manufacturing address,  Licence number,  
Batch number, Date of manufacture, 
Indication for External Use Only, Dose 
were included on all the labels, yet the 
main observation was that 92% drug labels 
did not have the standard of ingredients as 
per API written over them. Moreover 99% 
labels did not have the part of the 
ingredient used mentioned over it. Some 
drugs did not even mention the whole 
formulation composition either on label or 
as an insert leaflet inside the packing.  
Some serious flaws were observed 
pertaining to official names and botanical 
names also.  
Improper labelling gives 
incomplete or misleading information (e.g. 
which part of the plant is used as 
ingredient) about the drug, as a result of 
which the quality control methods of 
Identity, Purity and Strength as per API 
norms cannot be established. Transparency 
regarding the drug and its constituents 
cannot be maintained. It can be inferred 
from the above observations that the 
Ayurveda drugs manufacturing units are 
not serious about the provisions laid down 
in the Act.  This lack lustre attitude of the 
pharmacies has led to large scale 
marketing of Misbranded drugs.  
This situation can be improved by 
exploiting the services of the experts of 
Ayurveda who are well apprised of the 
laws and regulations pertaining to 
manufacturing of drugs. Regular 
inspections should be done and drug 
samples should be checked on every 
parameter of the Act. Emphasis should be 
given on quality control at every step of 
drug manufacturing and its marketing. 
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Moreover, the drug inspectors should be 
re-oriented and trained, so that they are 
able to check the non-compliance of the 
Act and its provisions. Also, legal action 
may be taken by the State Ayurvedic Drug 
Controlling Authority against such 
Ayurvedic Pharmacies manufacturing 
Misbranded drugs as per the provisions of 
D&C Act, 1940 so as to assure transparent 
and good quality products. 
This survey should act as an eye 
opener to the authorities as well as stake 
holders of the Ayurvedic pharmaceutical 
industry so that complete and correct 
information is provided on the labels and 
prevent the drugs from being termed as 
Misbranded. 
 
Conclusion  
The study highlights the 
seriousness of problem of Misbranding 
(not labelled as per law) of Ayurvedic 
drugs being marketed in India, as their 
labels do not give correct and complete 
information as per the Drugs & cosmetics 
Act, 1940 and amendments made into it 
from time to time. A study sample of 
hundred labels of classical and proprietary 
medicines of reputed houses has clearly 
brought out the violation of statutory 
provisions of D&C Act by major stake 
holders. Smaller regional manufacturers 
may be violating the act more seriously at 
the loss to the consumer. It is high time 
that regulatory authorities recognise the 
problem of misbranding of ASU drugs and 
take steps to enforce the provisions of 
D&C Act more seriously.  
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